Health Care/Hospital
Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape
TAIPEI and SAN DIEGO, March 3, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the signing of a major strategic Memorandum of Understa...
2026-03-03 15:51
5887
The largest pharma show in Asia makes its return to Shanghai this June 2026
SHANGHAI, March 2, 2026 /PRNewswire/ -- CPHI & PMEC China 2026 is set to take place from 16 to18 June 2026 at the Shanghai New International Expo Centre (SNIEC), building on its extremely successful run over the last few years. As the world's premier destination for pharmaceutical ingredients and...
2026-03-03 10:15
3839
XellSmart Receives Fourth Consecutive US FDA & China NMPA IND Clearance for MSA-P iPSC-derived Cell Therapy
SUZHOU, China, March 2, 2026 /PRNewswire/ -- In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart)announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its independently developed, off-the-shelf, allogeneic, uni...
2026-03-02 22:10
4430
ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven RNA-modulating small molecules to treat rare an...
2026-03-02 22:00
5030
Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®
PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and autoimmune diseases, proudly announced positive topline results from a Phase II clinical trial of it...
2026-03-02 22:00
4387
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
SHANGHAI, March 1, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 ("Yearbook") in recognition of its strong performance in the 2025...
2026-03-02 11:21
6197
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
SAN FRANCISCO and SUZHOU, China, March 1, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabol...
2026-03-02 08:00
6583
Dimora Medical Supports NPIAP 2026 Annual Conference as Exclusive Opening Ceremony Sponsor
NEW YORK, Feb. 28, 2026 /PRNewswire/ -- From February 26 to 27, the NPIAP 2026 Annual Conference was held inthe United States, bringing together leading clinicians, researchers, and healthcare professionals to advance the prevention and management of pressure injuries. Dimora Medical, a continuou...
2026-02-28 23:56
4844
BestQool's BQ60Pro: Next-Generation 6-Wavelength Home Red Light Therapy Device with Enhanced Output and Smarter Flexibility
NEW YORK, Feb. 27, 2026 /PRNewswire/ -- Since the launch of BestQool
2026-02-28 01:36
6652
Vatech Reports Industry-Leading 20-Year Patent Portfolio in Dental Diagnostic Imaging
Patent leadership reinforces company's leading position in the global CBCT market HWASEONG, South Korea, Feb. 27, 2026 /PRNewswire/ -- Vatech (KOSDAQ: 043150), a global manufacturer of dental imaging systems, announced that cumulative patent data over the past 20 years demonstrate its technologi...
2026-02-27 22:00
6178
WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform
SHANGHAI, Feb. 27, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced a strategic collaboratio...
2026-02-27 17:11
6520
Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform
WILMINGTON, Del., Feb. 27, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK) on WuXi XDC's proprietary WuXiTecan...
2026-02-27 15:00
5254
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference
SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG products has become a global phenomenon, and coupled with the side effects of BCG therapy itself,me...
2026-02-27 08:00
6147
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Highlights: * First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS * Approximately 160 participants with ALS will be enrolled in a 36-week randomised,double-blind, placebo-controlled adaptive Phase 2/3 clin...
2026-02-27 04:34
7482
SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
* SK–IDT–Vaxxas consortium establishes strategic entry point for high-density microarray patch (HD-MAP) vaccines inEurope to improve vaccine performance and access. * Parallel development of high-immunogenicity HD-MAP vaccines for seasonal and pandemic influenza threats. INCHEON, South Korea,...
2026-02-26 21:00
7303
CJ BIO Publishes Clinical Study on BiomeNrich™ POST SZ075, a Postbiotic Ingredient Demonstrating Skin Improvement Benefits
SEOUL, South Korea, Feb. 26, 2026 /PRNewswire/ -- CJ BIO announced the publication of clinical research findings on its postbiotic ingredient, BiomeNrich™ POST SZ075, in an international peer-reviewed journal. The study strengthens the scientific foundation of the ingredient and supports its pos...
2026-02-26 18:40
5454
Health Awareness Week Underscores the Importance of Respiratory Health
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- As Health Awareness Week brings focus
to preventive care and chronic condition management,VARON
2026-02-26 16:42
5202
Sanyou Biopharmaceuticals Announces New Strategic Investor; Liferiver Biotech Increases Its Stake, and Gree Group's Yanghe Investment Joins as a Strategic Shareholder
SHANGHAI, Feb. 24, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio"), a biotech company powered by super-trillion-molecule libraries and AI-driven technologies, today announced the completion of a significant equity restructuring. The shares previously held by Hai...
2026-02-24 22:00
6169
Graphy Accelerates U.S. Expansion, Positioning Shape Memory Aligners (SMA) at the Forefront of the Global Orthodontic Market
A strategic combination of the Florida SMA hub, Benco Dental's network, SCHEU alliance, and FUGO's multi-resin platform drives a global scale-up. * Florida Production Hub: Establishing a domestic manufacturing base to provide localized, order-based SMA solutions for U.S. clinicians. * Benco D...
2026-02-24 22:00
7847
"Would You Clone Yourself for a Cure?" Clonell Unveils White Paper on Fundamental Cures for 34 Incurable Diseases Using 'Human Cloning' Technology
Harnessing the vitality of a clone while neutralizing ethical controversies through a breakthrough 'Therapeutic Cloning' protocol—ushering in a new era of regenerative medicine to conquer cancer, Alzheimer's, and aging. YONGIN, South Korea, Feb. 23, 2026 /PRNewswire/ -- Human cloning has long be...
2026-02-23 21:40
3593
Week's Top Stories
Most Reposted
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 287 media titles]
2026-05-26 10:30
Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 285 media titles]
2026-05-27 09:16
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
[Picked up by 280 media titles]
2026-05-26 08:40
Consistently recognised: Infobip named a Leader in Gartner® Magic Quadrant™ for CPaaS again
[Picked up by 279 media titles]
2026-05-21 16:31
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
8900
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
8555
